FOR IMMEDIATE RELEASE:
November 22, 2015
Clear Thoughts Foundation (CTF) held its Roll for a Reason Gala on Friday, November 6th , 2015 at J. Verno Studio in the historic South Side area of Pittsburgh. CTF’s annual gala raises funds to further its mission to accelerate the discovery of drugs that will stop dementia.
A crowd of 325+ attendees helped CTF exceed its goal of raising $100,000 for dementia research. The Monte Carlo Casino Night was emceed by Star 100.7’s Bubba. Lots of fun was had by all who chanced their luck at poker, black jack, roulette, craps and slots. We thank our celebrity dealers in attendance for helping our guests enjoy the evening.
The evening was full of activity starting with an update from CTF Founder & President, Hayley Jameson, introducing a two-tier fundraising initiative that was recently approved by CTF’s Board of Directors. Tier 1 of the initiative is a long-term fundraising goal of $1,000,000 which will be directed towards an individual or organization on the cusp of a clinical trial for a drug to stop dementia. Tier 2 of the initiative will be an annual award of a research grant of approximately $50,000. The research grant application is currently on the CTF website and is available to any individual or organization currently doing research in the field of dementia.
The evening continued with a presentation by our Executive Scientific Director Susan Catalano that included the introduction of Dr. Steven DeKosky as CTF’s newest Scientific Advisor. Dr. DeKosky is one of the world’s leading experts in the causes of dementia. His distinguished record of scientific achievements adds a wealth of research and clinical experience to CTF’s Scientific Advisory Board. Dr. DeKosky’s strategic guidance is uniquely suited to assist with CTF’s mission to accelerate the discovery of drugs to stop dementia.
Clear Thoughts Foundation (CTF) is a 501(c)(3) not-for-profit organization. CTF was established in Pittsburgh in 2010, with the primary purpose to raise funds to discover drugs and novel therapeutics (biogenetics, stem cells, etc.) to stop the progression of dementia and eventually end this terrible disease. All of the founding members of CTF have had some personal experience with dementia, such as Alzheimer’s, or other related cognitive disorders, and have been disappointed with the lack of available and effective drugs and therapeutics in today’s market.
For further information contact Hayley Jameson at email@example.com